Arbutus Biopharma Corp: Form 10-Q for the period ended Jun 30, 2014
Filed with the SEC on Aug 14, 2014 and accepted by EDGAR at Aug 14, 2014, 16:50 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2014-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2014-04-01 to 2014-06-30 | $1.8m | us-gaap:Revenues |
| Revenue | 6 months2014-01-01 to 2014-06-30 | $6.2m | us-gaap:Revenues |
| Research and development | 3 months2014-04-01 to 2014-06-30 | $9.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2014-01-01 to 2014-06-30 | $17.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2014-04-01 to 2014-06-30 | −$9.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2014-01-01 to 2014-06-30 | −$15.4m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2014-04-01 to 2014-06-30 | −$6.1m | us-gaap:NetIncomeLoss |
| Net income | 6 months2014-01-01 to 2014-06-30 | −$24.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2014-04-01 to 2014-06-30 | −$0.28 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2014-01-01 to 2014-06-30 | −$1.15 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months2014-04-01 to 2014-06-30 | −$8.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Operating cash flow | 6 months2014-01-01 to 2014-06-30 | $1.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2014-04-01 to 2014-06-30 | $246.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Capital expenditure | 6 months2014-01-01 to 2014-06-30 | $581.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2014-06-30 | $85.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2014-06-30 | $118.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2014-06-30 | $132.1m | us-gaap:Assets |
| Current liabilities | At period end2014-06-30 | $16.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2014-06-30 | $26.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2014-06-30 | $105.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001171843-14-003980. Last ingested by Listed: Nov 12, 2026, 17:55 ET. Listed shows no prices and gives no investment advice.